(RTTNews) - Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on pruritus treatments, has announced the effective date of a 1-for-12 reverse stock split. Cara's common stock begined ...
The reverse stock split aims to help Cara Therapeutics regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Following the reverse stock split, ...
Cara's Therapeutics oral difelikefalin as adjunct therapy to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone. Among CARA's 3 late-stage programs, investors perhaps had the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results